Report Highlights

Gamma Knife Radiosurgery in the U.S.: Market Overview

The U.S. gamma knife market generated an estimated USD 310 million in 2024, a specialized slice of the broader radiation oncology equipment spend yet one with distinct structural features. Leksell Gamma Knife units deliver cobalt-60 photon beams through 192 fixed sources converging on a single isocenter, enabling sub-millimeter precision for intracranial targets. Unlike the global market, where linear accelerators dominate, U.S. installations cluster in neurosurgical and radiation oncology departments of large hospital systems.

Demand is structurally tied to reimbursement and licensing rather than hardware novelty. Elekta supplies the dominant installed base, but revenue is increasingly driven by service contracts and cobalt-60 source exchanges that recur every few years. Market value therefore tracks procedure volumes at roughly 250 active sites, each averaging several hundred cases annually across single-session and fractionated treatments. Each installation requires a capital outlay exceeding USD 4 million plus shielded vault construction.

Growth Drivers for Gamma Knife Radiosurgery in the U.S.

Brain metastases form the largest demand pool, with an estimated 200,000 U.S. patients diagnosed annually as lung and breast cancer survival improves. Medicare covers stereotactic radiosurgery under CPT codes 61796 through 61800, which anchors reimbursement for single-session cranial treatment. Clinicians increasingly prefer frameless Icon fractionation for elderly patients who cannot tolerate rigid head fixation, widening the eligible population. Benign indications such as vestibular schwannoma and trigeminal neuralgia add a steady referral base that rarely shifts to surgery.

The U.S. population aged 65 and over exceeds 60 million, and this cohort accounts for most meningioma and metastatic brain cases requiring intervention. Federal research funding from the National Cancer Institute supports comparative trials of radiosurgery against whole-brain radiotherapy, sustaining guideline adoption. Hospital systems including Cleveland Clinic and NYU Langone Health have expanded gamma knife programs to capture outpatient neuro-oncology volume. Medicare's 65-plus cohort is growing faster than the overall population, sustaining referral volume through 2032.

Market Restraints and Entry Barriers

Certificate-of-need regimes present the first barrier, as states including New York and Connecticut require regulatory approval before a hospital can install new radiation treatment equipment. Cobalt-60 sources fall under medical-use licensing in 39 Agreement States, which adopt NRC standards in 10 CFR Part 35, adding custody and leak-test obligations. Operators also face shielded vault construction costs and approval timelines that frequently exceed eighteen months before first patient treatment. Hospitals treat these hurdles as sunk costs before reimbursement begins.

Incumbent advantages are substantial, because Elekta's installed base, service network, and clinical training records create switching costs that deter hospitals from adopting rival platforms. Accuray's CyberKnife and Siemens Healthineers' Varian Edge compete for the same referrals with linear accelerator systems already in place across most radiation oncology departments. Medicare pays facility and professional fees under the Outpatient Prospective Payment System and Physician Fee Schedule, so bundled payment pressure compresses margins for independent centers.

Market Opportunities for Gamma Knife Entry in the U.S.

Replacement of aging Perfexion installations offers the nearest opportunity, since source exchanges and Icon upgrades will reprice roughly 250 active sites over the next seven years. Pre-owned unit resale and refurbishment represents an addressable pool estimated at USD 40 million annually, accessible to service-led entrants. Refurbished units also sell at prices materially below new Icon list pricing. Hospital consolidation also creates divestiture pipelines as systems such as HCA Healthcare rationalize neurosurgical service lines across their acute-care footprints.

Outpatient and freestanding gamma knife centers in high-growth Sun Belt metros, including Texas and Florida, remain underserved relative to population growth and neurosurgical referral density. Fractionated frameless treatment opens a pediatric and elderly niche where rivals have fewer validated indications, supporting premium per-case pricing. Entrants should target institutions with existing neurosurgery departments, because independent operators depend on physician referral networks that hospitals already control. Pricing discipline matters more than volume in this segment.

Market at a Glance

Leading Market Participants

• Elekta AB
• Accuray Incorporated
• Siemens Healthineers
• Brainlab AG
• US Neurosurgical Holdings
• HCA Healthcare
• Tenet Healthcare
• Cleveland Clinic
• Mayo Clinic
• NYU Langone Health

Regulatory and Policy Environment

The FDA regulates Leksell Gamma Knife systems as Class II devices through the 510(k) premarket notification pathway administered by the Center for Devices and Radiological Health. Radiation safety falls under the Nuclear Regulatory Commission's 10 CFR Part 35 medical-use rules, implemented by Agreement State agencies that issue source licenses and inspect shielded treatment vaults. Hospitals must also obtain certificate-of-need approval where state law requires it, and Joint Commission accreditation for radiation oncology services is typically required.

Reimbursement is governed by CMS through the Medicare Physician Fee Schedule and the Outpatient Prospective Payment System, with coverage determinations set by Medicare Administrative Contractors under local coverage determinations. No federal subsidy specifically supports gamma knife acquisition, so capital recovery depends on negotiated commercial payer rates and single-session volumes. Compliance timelines are material: source license renewals, annual radiation safety reviews, and CMS enrollment for professional billing typically require between three and six months of lead time.

Long-Term Outlook for Gamma Knife Radiosurgery in the U.S.

By 2032 the U.S. gamma knife market is projected to reach USD 420 million, growing at a 3.9% CAGR from its 2024 base as replacement cycles and fractionated indications sustain demand. Installed base growth will be modest, with net new sites concentrated in academic systems and Sun Belt metros, while source exchanges and service contracts generate a rising share of revenue. Elekta's Icon will remain the reference platform, while robotic and linear accelerator competitors hold share in community hospitals.

Market risk centers on reimbursement pressure and platform substitution rather than clinical demand. If CMS reduces professional payment rates for stereotactic procedures, smaller operators will exit, consolidating volume into large hospital groups such as HCA Healthcare and Tenet Healthcare. Cobalt-60 supply availability and decommissioning costs also shape the long-term cost curve for every installed unit. Operators planning beyond 2030 should budget for end-of-life decommissioning under NRC and state license conditions.